Drug intelligence / Profile preview

GTB-ALD-siRNA

Development stage: Preclinical
Lead developer: GeneToBe
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

GTB-ALD-siRNA is an investigational small interfering RNA (siRNA) therapy being developed by GeneToBe for the treatment of alcoholic liver disease (ALD). The drug utilizes RNA interference (RNAi) technology to silence specific, though currently undisclosed, pathogenic genes within the liver that contribute to the progression of ALD. As of early 2024, the program is in the IND-enabling stage of development, aiming to address the unmet medical need in patients suffering from liver damage caused by excessive alcohol consumption.

Other names: Alcoholic liver disease programGeneToBe ALD siRNA

Beyond the preview

Go deeper on GTB-ALD-siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GTB-ALD-siRNA.

Explore the full profile